We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
SciRhom GmbH, a therapeutic antibody company, announced the development of first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways ...